Zevra Therapeutics Inc (ZVRA)

03:22 AM

What drives Zevra Therapeutics Inc. stock priceOutstanding stock performance - PrintWeekIndia

03:22 AM

03:03 AM

What analysts say about Zevra Therapeutics Inc. stockSuperior stock growth - PrintWeekIndia

03:03 AM

Jul 23, 2025

Zevra Therapeutics Inc. Stock Analysis and ForecastExplosive wealth accumulation - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

Is Zevra Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com

Jul 23, 2025

Jul 18, 2025

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® - GlobeNewswire

Jul 18, 2025

Jul 18, 2025

Zevra Therapeutics: Promising Growth Driven by Miplyffa Success and Strategic Focus on Rare Diseases - TipRanks

Jul 18, 2025

Jul 18, 2025

ZVRA Showcases Key Findings on MIPLYFFA and OLPRUVA at Genetics - GuruFocus

Jul 18, 2025

Jul 18, 2025

Zevra Therapeutics Highlights Research on MIPLYFFA® and OLPRUVA® at 42nd Annual SERGG Meeting - Nasdaq

Jul 18, 2025

Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025

Jul 17, 2025

William Blair Issues Optimistic Forecast for ZVRA Earnings - Defense World

Jul 17, 2025

Jul 16, 2025

Zevra Therapeutics' MIPLYFFA: A Paradigm Shift in Rare Disease Treatment - AInvest

Jul 16, 2025

Jul 16, 2025

Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice - Yahoo Finance

Jul 16, 2025

Jul 16, 2025

5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com

Jul 16, 2025

Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025

Jul 16, 2025

Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C - Nasdaq

Jul 16, 2025

Jul 16, 2025

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism - The Manila Times

Jul 16, 2025

Jul 16, 2025

Breakthrough: New Clinical Data Shows MIPLYFFA Halts Rare Brain Disease Progression for 5 Years - Stock Titan

Jul 16, 2025

Jul 16, 2025

Niemann-Pick Disease Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - The Globe and Mail

Jul 16, 2025

Jul 15, 2025

ZVRA Publishes Positive Long-term Results for Arimoclomol in NPC Treatment | ZVRA Stock News - GuruFocus

Jul 15, 2025

Jul 15, 2025

Why Zevra Therapeutics Inc. stock attracts strong analyst attentionEarly Buy Suggestion - newser.com

Jul 15, 2025

Jul 15, 2025

What makes Zevra Therapeutics Inc. stock price move sharplyHigh Yield Stock Selection - Newser

Jul 15, 2025

Jul 15, 2025

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know - Yahoo Finance

Jul 15, 2025

Jul 15, 2025

Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA) - Yahoo Finance

Jul 15, 2025

Jul 15, 2025

How Zevra Therapeutics Inc. stock performs during market volatilityBreakout Momentum Alerts - Newser

Jul 15, 2025

Jul 15, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Analysts - Defense World

Jul 15, 2025

Jul 14, 2025

Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings - Defense World

Jul 14, 2025

Jul 12, 2025

Cantor Fitzgerald Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World

Jul 12, 2025

Jul 12, 2025

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen - Defense World

Jul 12, 2025

Jul 12, 2025

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) - GlobeNewswire

Jul 12, 2025

Jul 11, 2025

Zevra(ZVRA) Soars 4.41% on Phase 2 Trial, Strategic Collaboration - AInvest

Jul 11, 2025